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Targeting of gene regulatory factors to specific intranuclear sites
may be critical for the accurate control of gene expression. The
acute myelogenous leukemia 8;21 (AML1yETO) fusion protein is
encoded by a rearranged gene created by the ETO chromosomal
translocation. This protein lacks the nuclear matrix-targeting signal
that directs the AML1 protein to appropriate gene regulatory sites
within the nucleus. Here we report that substitution of the chro-
mosome 8-derived ETO protein for the multifunctional C terminus
of AML1 precludes targeting of the factor to AML1 subnuclear
domains. Instead, the AML1yETO fusion protein is redirected by the
ETO component to alternate nuclear matrix-associated foci. Our
results link the ETO chromosomal translocation in AML with
modifications in the intranuclear trafficking of the key hemato-
poietic regulatory factor, AML1. We conclude that misrouting of
gene regulatory factors as a consequence of chromosomal trans-
locations is an important characteristic of acute leukemias.
Modifications in nuclear morphology are a hallmark oftumor cells and are used for diagnosis. However, there is
limited knowledge of the subnuclear changes that accompany or
contribute to tumor-related alterations of nuclear architecture.
Biochemical evidence indicates that the protein composition of
the nuclear matrix is modified in tumor cells (1–7). The nuclear
matrix is a scaffold that provides a means for localizing genes and
regulatory factors throughout the nuclear space (8–11). Conse-
quently, analysis of targeting signals that direct regulatory
factors to nuclear matrix-associated subnuclear sites (12) may
provide insight into nuclear structure–function relationships
that are compromised in cancer.
The acute myelogenous leukemia (AML) transcription factor
AML11 is a key regulator of hematopoiesis (13, 14). Numerous
cytogenetic abnormalities that involve genes encoding AML1 or
its partner core binding factor b have been identified in AML
and acute lymphocytic leukemia (15–18). The frequent 8;21
translocation produces a chimeric protein (AML1yETO) in
which the C terminus of AML1 is replaced by the unrelated ETO
(MTG8) protein (19–23). The 8;21 translocation occurs in
approximately 15% of AML in adult patients (24–26).
The normal form of the AML1 protein has an N-terminal
region containing a runt homology DNA-binding domain (27)
and a multifunctional C-terminal region that supports transac-
tivation, repression, and intranuclear targeting (28–34). Alter-
native splicing of the AML1 gene can generate several protein
isoforms. The predominant isoform AML1B (480 aa) contains
a 31-aa nuclear matrix-targeting signal (NMTS) in the C termi-
nus. This targeting signal is necessary and sufficient to direct the
factor to nuclear matrix-associated subnuclear sites that support
transcription (30). Many of these AML1 sites are localized
together with the hyperphosphorylated active form of RNA
polymerase IIo, and this association requires the presence of the
runt homology domain of AML1B (35).
The AML1yETO fusion product is expressed from the AML
promoter and contains the DNA-binding domain of AML1 and
all but the first 30 aa of the ETO protein (19, 20, 36). However,
this fusion protein lacks the AML1 multifunctional C terminus,
including its subnuclear targeting signal. The ETO protein that
replaces it is a highly conserved gene regulatory factor related to
nervy, a Drosophila homeotic target gene product (20, 37–41).
The AML1yETO fusion protein acts as a dominant-negative
factor in mice (42) and in transient assays is a dominant-negative
regulator of AML1B-mediated transcriptional activation (43).
Additionally, AML1yETO blocks myeloid differentiation (40,
44). AML1yETO may prevent apoptosis by activating the Bcl2
promoter (45) and causes cellular transformation of NIH 3T3
cells (46). Thus, the t(8;21) lesion compromises normal regula-
tory properties of the AML1 protein by relinquishing AML1-
encoded functions and acquiring ETO-related characteristics.
Targeting of gene regulatory factors to specific subnuclear
sites may be critical for accurate control of gene expression.
Consequently, AML1yETO provides a paradigm for experimen-
tally addressing whether loss of the AML1B NMTS compro-
mises the subnuclear trafficking of AML factors. Here we show
that the AML1yETO protein is directed to intranuclear sites that
do not overlap AML1 domains. Instead, the subnuclear targeting
of the fusion protein is controlled by an ETO intranuclear
targeting signal. Thus, our findings indicate that the misrouting
of gene regulatory factors as a consequence of gene rearrange-
ment is an important characteristic of translocation-associated
leukemias.
Materials and Methods
Cell Culture. Saos-2 cells were grown in McCoy’s 5A Medium
(GIBCOyBRL) supplemented with 15% FBS.
Transient Transfections. Saos-2 cells were plated on 0.5% gelatin
coated coverslips (Fisherbrand, no. 12–545-101, 22cir-1; Fisher)
in 6-well tissue culture trays at a density of 0.2 3 106 cellsywell.
Cells were grown approximately 18 h after plating on coverslips
in McCoy’s 5A 1 15% FBS. Cell density was approximately 50%
at the time of transfection. Saos-2 cells were transfected by using
either calcium phosphate (47) or Superfect as described by the
manufacturer (Qiagen, Chatsworth, CA) with identical results. It
was essential to achieve low levels of expression per cell to
analyze colocalization. Optimization of the Superfect procedure
included using 250 ng of expression vector and 5 ml of Superfect
reagent per well. Cells were processed for immunofluorescence
Abbreviations: AML, acute myelogenous leukemia; ETO, eight; twenty one protein; NMTS,
nuclear matrix-targeting signal; NM-IF, nuclear matrix–intermediate filament; HA, hem-
agglutinin; EGFP, enhanced green fluorescent protein.
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18 h after transfection, as described below (except when noted
otherwise). Epitope-tagged DNA constructs used in these ex-
periments are described below.
Plasmids. Plasmids hemagglutinin epitope (HA)-AML1B, HA-
AML1yETO, and Flag-ETO were constructed as described (30,
48, 49). Plasmid enhanced green fluorescent protein (EGFP)-
AML1B was constructed by fusing the AML1B coding sequence
(amino acids 27–480) in frame with an EGFP epitope tag cloned
into pcDNA3.
Cell Extraction and Fixation. Cells were processed for whole-cell or
nuclear matrix–intermediate filament (NM-IF), as described
previously (50).
Immunofluorescence. PBS-A (PBS containing 0.5% BSA) was
used to block nonspecific antibody binding, as the wash solution,
and for antibody dilution, unless otherwise indicated. Antisera
were as follows: a rabbit polyclonal antiserum to the HA epitope
was diluted 1:1,000 (Santa Cruz Biotechnology, no. sc805); a
mouse monoclonal antibody to the Flag-epitope was diluted
1:1,000 (Kodak, no. IB13010 or Sigma, no. F3165); a mouse
monoclonal antibody to human promyelocytic leukemia was
diluted 1:1,000 (Santa Cruz Biotechnology, no. SC966); and a
rabbit polyclonal to ETO protein was diluted 1:500. Diluted
antibody was added as a 50-ml drop to coverslips in wells, covered
lightly with Parafilm, and incubated for 1 h at 37°C or overnight
at 4°C. Coverslips were rinsed four times with PBS-A, and
secondary antibody was added. Secondary antibody was goat
anti-rabbit IgG conjugated to fluorescein or Texas red or
Donkey anti-mouse IgG conjugated to fluorescein or Texas red
(Jackson ImmunoResearch), diluted 1:500, added to coverslips,
and incubated 1 h at 37°C. After incubation, coverslips were
rinsed four times with PBS-A; one time with PBS-A containing
0.1% Triton X-100 and 0.05 mgyml of the DNA counterstain
49,6-diamidino-2-phenylindole (DAPI); one time with PBS-A
containing 0.1% Triton X-100; and twice in PBS. Coverslips
were mounted in Vectashield (Vector Laboratories) as an
antifade mounting medium.
Microscopy. A Zeiss Axioplan 2 microscope equipped with epi-
f luorescence filters and a charge-coupled device camera inter-
Fig. 1. The chimeric AMLyETO fusion protein is directed to the nuclear matrix in situ in the absence of the AML1B NMTS. Immunofluorescence localization of
AML1B (Top), AMLyETO (Middle), and ETO (Bottom) proteins expressed in Saos-2 cells was examined in whole-cell (Left) and in situ nuclear-matrix (NMIF, Right)
preparations by using specific antibodies to detect the epitope-tagged proteins and visualized by using a FITC secondary antibody. 49,6-diamindino-2-
phenylindole (DAPI) staining was used to evaluate DNA content and is shown (Inset) for each image. (Bar 5 10 mm.)
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faced with the MetaMorph Imaging System (Universal Imaging,
Media, PA) was used.
Results
Subnuclear Targeting of the t(8;21) AML1yETO Translocation Fusion
Protein. There are at least three signals in the AML1B transcrip-
tion factor that determine its subcellular location. The nuclear
localization signal of AML1 is required for nuclear import (28),
whereas its NMTS directs it to the appropriate sites on the
nuclear matrix (30). The DNA binding domain facilitates linkage
with transcriptionally active subnuclear foci (35).
The AML1yETO translocation results in the removal of the
AML NMTS from the DNA-binding domain of the AML1
protein. The loss of the NMTS should result in aberrant intranu-
clear targeting of AML1. To determine the location of the
AML1yETO fusion protein, we examined whole-cell and NM-IF
preparations of Saos-2 cells transfected with epitope-tagged
AML1B and AML1yETO expression constructs. Expressed
proteins were detected with epitope-specific antibodies and
visualized by using an epifluorescence microscope interfaced
with a digital imaging system. We observed that both AML1B
and AML1yETO proteins were present in whole-cell prepara-
tions (Fig. 1). As reported previously, AML1B was retained in
the NM-IF fraction. However, the AML1yETO fusion protein,
which lacks the AML1B NMTS, was nevertheless associated with
the NM-IF (Fig. 1). Thus, the ETO moiety may contain a
compensatory subnuclear targeting signal that supports nuclear
matrix association and substitutes for the AML1B NMTS. To
test this possibility directly, we analyzed the subnuclear distri-
bution of the ETO protein. The results (Fig. 1) show that ETO
indeed associates with the nuclear matrix and suggest that the
ETO protein contains an independent subnuclear targeting
signal. The presence of this signal in the AML1yETO fusion
protein apparently serves to direct the chimeric protein to the
nuclear matrix in the absence of the AML NMTS.
AML1 and the AML1yETO Fusion Protein Are Targeted to Different
Subnuclear Locations. To assess whether loss of the AML1 NMTS
andyor fusion of ETO sequences results in an altered spatial
distribution of AML1B, we next compared the nuclear matrix-
associated foci containing AML1B with those containing the
translocation gene product AML1yETO. Saos-2 cells were co-
A
Fig. 2. AML1B and AMLyETO proteins are targeted to distinct subnuclear locations. Immunofluorescence localization of coexpressed proteins in Saos-2 cells
was examined in in situ nuclear-matrix preparations by using digital fluorescence microscopy (A) or laser-scanning confocal microscopy (B). AML and ETO
coexpression (Top), AML and AMLyETO coexpression (Middle), and AMLyETO and ETO coexpression (Bottom). Epitope-tagged proteins were detected with
specific antibodies and visualized by using a Texas red-conjugated secondary antibody seen as a red fluorescent signal (r, red, Center), and either a FITC secondary
antibody or an EGFP epitope tag, seen as a green fluorescent signal (g, green, Left). Colocalization of red and green immunofluorescence signals is observed as
yellow staining in the merged images (Right). (Figure continues on the opposite page.)
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transfected with equal concentrations of AML1B and AML1y
ETO epitope-tagged expression constructs and extracted to
obtain the NM-IF fraction. The epitope-tagged proteins were
visualized by using digital f luorescence microscopy or laser-
scanning confocal microscopy. AML1B and AML1yETO are
both observed as punctate nuclear signals, one red and one
green, that are associated with the nuclear matrix. There is only
a minor yellow signal, indicating very little overlap of the
fluorescent signals of the two expressed proteins (Fig. 2). Thus
the AML1yETO fusion protein is targeted to subnuclear sites
within the nuclear matrix different from those of the full-length
AML1B protein. We conclude that the substitution for the
AML1B C terminus results in misrouting of the AML gene
regulatory factor within the nucleus.
We then analyzed the subnuclear locations of coexpressed
AML1B and ETO proteins (Fig. 2). Similar to the results for
AML1B and AML1yETO, minimal overlap is observed with
these expressed proteins, and most sites are detected as distinct
green or red immunofluorescence signals, respectively. The
results show that the majority of AML1B and ETO proteins do
not colocalize. Hence, AML1B and ETO are directed to distinct
subnuclear compartments, which may reflect differences in the
regulatory activities of these factors.
To address the specificity of subnuclear targeting, we com-
pared the subnuclear distribution of AML1B proteins contain-
ing different epitope tags. We cotransfected HA-AML1B and
EGFP AML1B into Saos-2 cells and examined the localization
of the expressed proteins, as described above. The data show that
the majority of the expressed proteins are targeted to the same
nuclear matrix-associated foci, because they are detected mostly
as colocalizing yellow immunofluorescence signals (Fig. 3). We
conclude that coexpression of AML1B with two different
epitope tags (HA and EGFP) results in targeting to the same
subnuclear compartment. Thus, epitope tagging does not inter-
fere with specificity of intranuclear targeting.
We evaluated whether the ETO portion of AML1yETO
redirects the fusion protein to the ETO containing foci associ-
ated with the nuclear matrix. ETO and AML1yETO were
cotransfected into Saos-2 cells, and the intranuclear localization
of both proteins was analyzed. In contrast to the other pairs of
proteins examined, we find that the majority of ETO and
AML1yETO signals overlap, as reflected by mostly yellow
immunofluorescence signal in the merged image (Fig. 2). There-
fore, AML1yETO and ETO are targeted to the same subnuclear
compartment of the nuclear matrix. Taken together, our results
show that the fusion of ETO with AML1 results in misdirected
targeting of the AML DNA-binding domain to subnuclear foci
that are determined by the ETO protein.
Discussion
Our results link the 8;21 chromosomal translocation in AML
with modifications in the intranuclear trafficking of a key
hematopoietic regulatory factor, AML1. Our principal finding is
that substitution of the multifunctional C terminus of AML1
B
Fig. 2. (Continued from previous page.)
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with the chromosome 8-derived ETO protein precludes target-
ing of the factor to AML1 subnuclear domains. Instead, the
AML1yETO fusion protein is redirected to different nuclear
foci. We have also demonstrated that AML1yETO and ETO can
localize at the same intranuclear sites. Thus, our results show that
AML1 does not affect ETO trafficking and suggest that ETO
contains a targeting signal that specifies a distinct intranuclear
address.
The leukemia-related AML1 and promyelocytic leukemia
proteins have previously been identified as nuclear matrix-
associated factors, consistent with recent findings by others (23,
34). Here we report that AML1yETO and ETO are also nuclear
matrix associated. This association of multiple distinct factors is
in agreement with the concept that the nuclear matrix supports
the dynamic organization of functionally specialized foci that are
spatially distinct. Taken together, our findings suggest that
nuclear matrix-related mechanisms for spatial targeting and
subnuclear organization of regulatory factors are aberrant in
leukemia cells.
Regulation of the proximity of genes and cognate transcrip-
tion factors may be mediated by specific targeting signals.
Experimental support for this trafficking mechanism is provided
by the recent identification of a sequence- and structure-specific
NMTS in the AML1 protein (30, 51). The NMTS directs this
hematopoietic transcription factor to nuclear matrix-associated
foci that support gene expression (35). Other classes of gene
regulatory factors, including the androgen and glucocorticoid
receptors (52, 53), Pit-1 (54), and YY-1 (50, 55), have also been
shown to contain NMTSs that differ from the AML1 NMTS.
This diversity of trafficking signals may provide the requisite
specificity to direct factors to independent subnuclear locations.
An important ramification of this model is that molecular
alterations may cause misrouting of transcription factors result-
ing in compromised gene expression and development of dis-
ease. The t(8;21) fusion protein provides a striking demonstra-
tion of the functional consequences of altered subnuclear tar-
geting. Our findings show that this translocation rearranges the
normal targeting signals of AML1 and ETO and misroutes the
fusion protein away from AML1 foci. This misdirected targeting
may directly contribute to the deregulation of AML1 responsive
genes observed in t(8;21)-related AMLs. In a broader perspec-
tive, deregulation of transcription factor targeting may be fun-
damental to aberrations in gene expression characteristic of
many leukemias and other tumors involving chromosomal trans-
locations.
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